Revolution Medicines falls after Incyte posts competitive pancreatic cancer data

Incyte

26/10/2026 16:04

** Shares of Revolution Medicines RVMD.O down 1% at $185.06 
** Incyte INCY.O reports an 89% response rate for its KRAS G12D drug zecdarasib in a pancreatic cancer study at ESMO; with RBC Capital Markets analysts saying the results appear broadly competitive with RVMD's zoldonrasib but not clearly differentiated
** Both companies are developing similar drugs for KRAS G12D-mutant pancreatic cancer, making them key rivals in the space
** RBC says Incyte's pancreatic cancer data showed no major surprises, with response rates and safety largely in line with expectations and comparable to those previously reported by Revolution
** Brokerage notes INCY's zecdarasib remains on a similar development timeline, with late-stage pancreatic cancer data expected in 2028
** RBC says the two companies remain "neck-and-neck", with longer-term survival data likely to determine the winner
** Including session moves, RVMD has been doubled YTD

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))